home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences

Search

 
  IBC's The Impact of Post-Translational & Chemical Modifications on Protein Therapeutics  
  July 17, 2003

Biochemistry / Immunology

 
     
  IBC Life Sciences, Sheraton Premier at Tysons Corner, Vienna, VA
November 12-14, 2003


Learn to utilize post-translational changes for advancing your therapeutic protein while precluding expensive setbacks due to unnecessary modifications. IBC has gathered industry and academic leaders to share their diverse experience and proposed solutions for challenges in post-translational and chemical modifications of recombinant therapeutic proteins which occur during production, manufacturing and analysis of therapeutics. Plus, take in a short course on Immunogenicity of Recombinant Biological Therapeutics while your there! For full conference details and to register, visit www.LifeSciencesInfo.com/PTM.
 
 
Organized by: IBC Life Sciences
Invited Speakers: Keynote Address:

"Immunogenicity of Biological Therapeutics and Potential Approaches to Tolerance Induction"
- Amy Rosenberg, M.D., Director of the Division of Therapeutic Proteins, CDER, US FDA

 
Deadline for Abstracts: -
 
Registration: Phone: (508) 616-5550 x1004 Fax: (508) 616-5522 Email: reg@ibcusa.com Online: www.LifeSciencesInfo.com/PTM
E-mail: reg@ibcusa.com
 
  Posted by:   James G. Prudhomme  
Host: host-65-124-112-226.ibcusa.com
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.